Annual CFF
$180.02 M
+$165.93 M+1177.46%
December 31, 2023
Summary
- As of February 7, 2025, SLNO annual cash flow from financing activities is $180.02 million, with the most recent change of +$165.93 million (+1177.46%) on December 31, 2023.
- During the last 3 years, SLNO annual CFF has risen by +$126.30 million (+235.09%).
- SLNO annual CFF is now at all-time high.
Performance
SLNO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$2.27 M
-$150.47 M-98.51%
September 30, 2024
Summary
- As of February 7, 2025, SLNO quarterly cash flow from financing activities is $2.27 million, with the most recent change of -$150.47 million (-98.51%) on September 30, 2024.
- Over the past year, SLNO quarterly CFF has dropped by -$37.13 million (-94.23%).
- SLNO quarterly CFF is now -98.51% below its all-time high of $152.75 million, reached on June 30, 2024.
Performance
SLNO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$279.52 M
-$37.13 M-11.72%
September 30, 2024
Summary
- As of February 7, 2025, SLNO TTM cash flow from financing activities is $279.52 million, with the most recent change of -$37.13 million (-11.72%) on September 30, 2024.
- Over the past year, SLNO TTM CFF has increased by +$223.06 million (+395.07%).
- SLNO TTM CFF is now -11.72% below its all-time high of $316.65 million, reached on June 30, 2024.
Performance
SLNO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SLNO Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1177.5% | -94.2% | +395.1% |
| 3 y3 years | +235.1% | -94.2% | +395.1% |
| 5 y5 years | +909.8% | -94.2% | +395.1% |
SLNO Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -98.5% | +906.7% | -11.7% | >+9999.0% |
| 5 y | 5-year | at high | >+9999.0% | -98.5% | +906.7% | -11.7% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -98.5% | +906.7% | -11.7% | >+9999.0% |
Soleno Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.27 M(-98.5%) | $279.52 M(-11.7%) |
| Jun 2024 | - | $152.75 M(>+9900.0%) | $316.65 M(+75.0%) |
| Mar 2024 | - | $938.00 K(-99.2%) | $180.96 M(+0.5%) |
| Dec 2023 | $180.02 M(+1177.5%) | $123.56 M(+213.6%) | $180.02 M(+218.8%) |
| Sep 2023 | - | $39.40 M(+131.0%) | $56.46 M(+224.5%) |
| Jun 2023 | - | $17.06 M(>+9900.0%) | $17.40 M(>+9900.0%) |
| Mar 2023 | - | $0.00(0.0%) | $60.00 K(-99.6%) |
| Dec 2022 | $14.09 M(<-9900.0%) | $0.00(-100.0%) | $14.09 M(+0.0%) |
| Sep 2022 | - | $342.00 K(-221.3%) | $14.09 M(+2.5%) |
| Jun 2022 | - | -$282.00 K(-102.0%) | $13.74 M(-2.0%) |
| Mar 2022 | - | $14.03 M(<-9900.0%) | $14.03 M(<-9900.0%) |
| Dec 2021 | -$128.00 K(-100.2%) | -$5000.00(<-9900.0%) | -$128.00 K(-22.4%) |
| Sep 2021 | - | $0.00(-100.0%) | -$165.00 K(-54.2%) |
| Jun 2021 | - | $2000.00(-101.6%) | -$360.00 K(-100.7%) |
| Mar 2021 | - | -$125.00 K(+197.6%) | $53.60 M(-0.2%) |
| Dec 2020 | $53.72 M(+271.0%) | -$42.00 K(-78.5%) | $53.72 M(-21.3%) |
| Sep 2020 | - | -$195.00 K(-100.4%) | $68.25 M(-0.3%) |
| Jun 2020 | - | $53.96 M(<-9900.0%) | $68.44 M(+372.7%) |
| Mar 2020 | - | -$4000.00(-100.0%) | $14.48 M(-0.0%) |
| Dec 2019 | $14.48 M(-18.8%) | $14.48 M(>+9900.0%) | $14.48 M(-11.2%) |
| Sep 2019 | - | $0.00(0.0%) | $16.30 M(-4.1%) |
| Jun 2019 | - | $0.00(0.0%) | $17.00 M(-3.1%) |
| Mar 2019 | - | $0.00(-100.0%) | $17.54 M(-1.6%) |
| Dec 2018 | $17.83 M | $16.30 M(+2228.9%) | $17.83 M(+13.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $700.00 K(+30.4%) | $15.70 M(+4.7%) |
| Jun 2018 | - | $537.00 K(+86.5%) | $14.99 M(+3.7%) |
| Mar 2018 | - | $288.00 K(-98.0%) | $14.46 M(-40.2%) |
| Dec 2017 | $24.17 M(+124.5%) | $14.17 M(>+9900.0%) | $24.17 M(+141.7%) |
| Sep 2017 | - | $0.00(0.0%) | $10.00 M(-36.3%) |
| Jun 2017 | - | $0.00(-100.0%) | $15.70 M(-0.4%) |
| Mar 2017 | - | $10.00 M(>+9900.0%) | $15.77 M(+46.4%) |
| Dec 2016 | $10.77 M(+17.6%) | $100.00(-100.0%) | $10.77 M(-28.0%) |
| Sep 2016 | - | $5.70 M(+8040.0%) | $14.95 M(+41.5%) |
| Jun 2016 | - | $70.00 K(-98.6%) | $10.56 M(-2.0%) |
| Mar 2016 | - | $5.00 M(+19.5%) | $10.78 M(+17.7%) |
| Dec 2015 | $9.16 M(-18.3%) | $4.18 M(+219.7%) | $9.16 M(-36.6%) |
| Sep 2015 | - | $1.31 M(+364.2%) | $14.45 M(+9.0%) |
| Jun 2015 | - | $282.00 K(-91.7%) | $13.26 M(-9.1%) |
| Mar 2015 | - | $3.38 M(-64.3%) | $14.59 M(+30.2%) |
| Dec 2014 | $11.20 M(>+9900.0%) | $9.48 M(+7866.4%) | $11.20 M(+550.2%) |
| Sep 2014 | - | $119.00 K(-92.6%) | $1.72 M(+7.4%) |
| Jun 2014 | - | $1.60 M(>+9900.0%) | $1.60 M(>+9900.0%) |
| Mar 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2013 | $0.00(-100.0%) | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2013 | - | -$200.00(-200.0%) | $0.00(-100.0%) |
| Jun 2013 | - | $200.00(>+9900.0%) | $200.00(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | $5.03 M | - | - |
FAQ
- What is Soleno Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Soleno Therapeutics?
- What is Soleno Therapeutics annual CFF year-on-year change?
- What is Soleno Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Soleno Therapeutics?
- What is Soleno Therapeutics quarterly CFF year-on-year change?
- What is Soleno Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Soleno Therapeutics?
- What is Soleno Therapeutics TTM CFF year-on-year change?
What is Soleno Therapeutics annual cash flow from financing activities?
The current annual CFF of SLNO is $180.02 M
What is the all time high annual CFF for Soleno Therapeutics?
Soleno Therapeutics all-time high annual cash flow from financing activities is $180.02 M
What is Soleno Therapeutics annual CFF year-on-year change?
Over the past year, SLNO annual cash flow from financing activities has changed by +$165.93 M (+1177.46%)
What is Soleno Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SLNO is $2.27 M
What is the all time high quarterly CFF for Soleno Therapeutics?
Soleno Therapeutics all-time high quarterly cash flow from financing activities is $152.75 M
What is Soleno Therapeutics quarterly CFF year-on-year change?
Over the past year, SLNO quarterly cash flow from financing activities has changed by -$37.13 M (-94.23%)
What is Soleno Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SLNO is $279.52 M
What is the all time high TTM CFF for Soleno Therapeutics?
Soleno Therapeutics all-time high TTM cash flow from financing activities is $316.65 M
What is Soleno Therapeutics TTM CFF year-on-year change?
Over the past year, SLNO TTM cash flow from financing activities has changed by +$223.06 M (+395.07%)